Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
2 results
Filters applied: . Clear all
Page 1
Macitentan and morbidity and mortality in pulmonary arterial hypertension.
N Engl J Med. 2013 Aug 29;369(9):809-18. doi: 10.1056/NEJMoa1213917.
N Engl J Med. 2013.
PMID: 23984728
Free article.
Clinical Trial.
BACKGROUND: Current therapies for pulmonary arterial hypertension have been adopted on the basis of short-term trials with exercise capacity as the primary end point. We assessed the efficacy of macitentan, a new dual endothelin-receptor antagonist, using a primary end poi …
BACKGROUND: Current therapies for pulmonary arterial hypertension have been adopted on the basis of short-term trials with exercise c …
[Personal experience in the diagnosis and therapy of pulmonary thromboembolism].
Mitić-Milikić M, Miladinović D, Stanković V.
Mitić-Milikić M, et al.
Srp Arh Celok Lek. 1992 Jul-Aug;120(7-8):233-6.
Srp Arh Celok Lek. 1992.
PMID: 1306009
Serbian.
In addition, the presence of risk factors related to the development of thrombosis of the lower limbs deep veins, and particularly those related to the long term immobilization as well as diagnostically confirmed venous thrombus are basic guidelines for the diagnostic of p …
In addition, the presence of risk factors related to the development of thrombosis of the lower limbs deep veins, and particularly those rel …
Item in Clipboard
Cite
Cite